A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing
A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing
复制标题
DOI：
10.1007/s13691-021-00482-2
复制
发表时间：
2021-04-13
影响因子：
0.7
通讯作者：
Oya, Mototsugu
中科院分区：
文献类型：
--
作者：
Hongo, Hiroshi;Kosaka, Takeo;Oya, Mototsugu
目前尚不清楚无细胞DNA(CfDNA)能否取代实体组织活检。一位59岁男性患上了耐去势前列腺癌，并伴有肝转移。我们进行了肝脏活检，并收集了cfDNA样本。虽然他接受了射频消融，但肿瘤复发，他被转移到另一家医院。我们使用活检组织的DNA和cfDNA进行了下一代测序。在活检组织和cfDNA中均检测到BRCA2p.T3033fs和AURKA F31I。CfDNA可作为液体活检用于监测侵袭性前列腺癌的基因图谱。
It is still unclear whether cell-free DNA (cfDNA) can replace solid-tissue biopsy. A 59-year-old man developed castration-resistant prostate cancer with a liver metastasis. We performed a liver biopsy and collected a cfDNA sample. Although he underwent radiofrequency ablation, tumors recurred and he was transferred to another hospital. We performed next-generation sequencing using DNA from the biopsy tissue and cfDNA. BRCA2 p.T3033fs and AURKA F31I were detected in both the biopsy tissue and the cfDNA. cfDNA may be useful as a liquid biopsy for monitoring the gene profile of aggressive prostate cancer.